Yervoy for First Line Advanced Melanoma - Details

Détails

Fichiers
Generic Name:
Ipilimumab
État du projet:
Terminé
Domaine thérapeutique:
First Line Advanced Melanoma
Fabricant:
Bristol-Myers Squibb Canada
Brand Name:
Yervoy
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0042-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
5mg/mL
Tumour Type:
Peau et mélanome
Indications:
First Line Advanced Melanoma
Funding Request:
For the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.